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SUMMARY 1 
Influenza A virus (IAV) infection is initiated by the attachment of the viral glycoprotein 2 
hemagglutinin (HA) to sialic acid on the host cell surface.   However, the sialic acid–3 
containing receptor crucial for IAV infection has remained unidentified. Here we show 4 
that HA binds to the voltage-dependent Ca2+ channel Cav1.2 to trigger intracellular Ca2+ 5 
oscillations and subsequent IAV entry and replication.  IAV entry was inhibited by Ca2+ 6 
channel blockers (CCBs) or by knockdown of Cav1.2. The CCB diltiazem also inhibited 7 
virus replication in vivo. Reintroduction of wild-type but not the glycosylation-deficient 8 
mutants of Cav1.2 restored Ca2+ oscillations and virus infection in Cav1.2-depleted cells, 9 
demonstrating the significance of Cav1.2 sialylation. Taken together, we identify Cav1.2 10 
as a sialylated host cell surface receptor that binds HA and is critical for IAV entry. 11 
 12 
INTRODUCTION 13 
Influenza is a human respiratory infection caused by influenza viruses, and spreads worldwide 14 
in an annual outbreak or does occasionally in pandemics, resulting in significant morbidity 15 
and mortality (Herfst et al., 2012). The primary event in influenza virus infection is the 16 
attachment of virus particles to the host cell surface, which is mediated by the binding of HA 17 
to sialylated cell surface receptors on respiratory or intestinal epithelial cells in humans and 18 
birds, respectively (Kumlin et al., 2008). Avian viruses bind preferentially to receptors with 19 
α2,3-linked sialic acid moieties, whereas human-adapted viruses are specific for the α2,6 20 
linkage (Connor et al., 1994; Rogers and D'Souza, 1989). This specificity is key to 21 
determination of the host range of each viral strain. Given that the sialic acid that contributes 22 
to the binding of HA to the cell surface may be presented on a glycoprotein, many studies 23 
have attempted to identify specific IAV receptor protein(s). Such identified proteins include 24 
the killer-activating proteins NKp44 and NKp46 in natural killer cells (Achdout et al., 2010; 25 
Arnon et al., 2004; Ho et al., 2008; Mandelboim et al., 2001), as well as the epidermal growth 26 
factor receptor in lung epithelial cells (Eierhoff et al., 2010). However, the binding of IAV to 27 
sialylated cell surface proteins does not always result in receptor-mediated internalization 28 
(Carroll and Paulson, 1985; Williams and Robertson, 1993), suggesting that the engagement 29 
of specific cellular signaling may be required to initiate virus endocytosis. 30 
 IAVs enter host cells via redundant endocytic pathways, including clathrin-mediated 31 
endocytosis, clathrin-independent endocytosis, and Macropinocytosis (Chen and Zhuang, 32 
2008; Doxsey et al., 1987; Fujioka et al., 2011; 2013; Matlin et al., 1981; Rust et al., 2004; 33 
 3 
Sieczkarski and Whittaker, 2002). It has been previously demonstrated that intracellular Ca2+ 1 
plays a central role in upregulating such endocytic pathways (Fujioka et al., 2013). Indeed, 2 
IAV infection induces Ca2+ oscillations of host cells, and the infection is markedly attenuated 3 
by the chelation of both intracellular and extracellular Ca2+ by BAPTA-AM and EGTA, 4 
respectively (Fujioka et al., 2013), suggesting that Ca2+ flux from the outside to the inside of 5 
cell may also play a role in the regulation of IAV entry and infection. 6 
The intracellular calcium ion concentration ([Ca2+]i) is normally maintained at a low 7 
level by various membrane transporters including Na+-Ca2+ exchangers and Ca2+-dependent 8 
ATPases at the plasma membrane, sarco-endoplasmic reticulum Ca2+-ATPases (SERCAs) 9 
and a Ca2+-H+ exchanger in mitochondria as well as by cytoplasmic Ca2+-binding proteins 10 
(Berridge et al., 2003). Cell stimulation with various ligands triggers an increase in [Ca2+]i 11 
that results from the activation of Ca2+ channels including voltage-dependent calcium 12 
channels (VDCCs), inositol 1,4,5-trisphosphate (IP3)-gated Ca2+ channels and ryanodine 13 
receptors. Among them, VDCCs might be a candidate that mediate the IAV-induced increase 14 
in [Ca2+]i in host cells, because (1) these channels are expressed at the plasma membrane, (2) 15 
their function is modified by sialylation (Ednie and Bennett, 2012), (3) one of the calcium 16 
channel blockers (CCBs), verapamil, inhibits IAV replication by an unknown mechanism 17 
(Nugent and Shanley, 1984) and (4) extracellular Ca2+ is also important for the IAV-induced 18 
increase in [Ca2+]i (Fujioka et al., 2013). In this study, we demonstrated that the VDCC 19 
Cav1.2 (encoded by the CACNA1C gene) bound to IAV HA. The binding through sialic acid 20 
was crucial for IAV infection, entry, and IAV-induced Ca2+ oscillation. The effect of the 21 
CCBs on virus infection was also demonstrated in vitro, ex vivo, and in vivo. Taken together, 22 
our analysis revealed that Cav1.2 acts as a key cell surface molecule for IAVs to hijack host 23 
cell machinery of endocytosis for their efficient incorporation into host cells. 24 
  25 
 4 
RESULTS 1 
CCBs Suppress IAV Replication, IAV Internalization, and IAV-Induced Ca2+ 2 
Oscillations 3 
To test whether VDCCs play a role in IAV infection, we first evaluated the effect of 4 
CCBs on the plaque-forming activity of the IAV strains A/Puerto Rico/8/34 (H1N1; PR8) in 5 
Madin-Darby canine kidney (MDCK) cells. All tested CCBs, including amlodipine, 6 
verapamil, and diltiazem, as well as BAPTA-AM, inhibited IAV replication in a dose-7 
dependent manner (Figure S1A).  Based on their IC95 values, amlodipine, verapamil, 8 
diltiazem, and BAPTA-AM were used at concentrations of 25, 50, 200, 25 M, respectively, 9 
in the following experiments. Of note, treatment with drugs at these concentrations displayed 10 
no significant toxicity in MDCK cells (Figure S1B). The treatment with CCBs resulted in 11 
inhibition of replication of both PR8 and A/Aichi/2/68 (H3N2; Aichi) with the exception that 12 
verapamil did not significantly inhibit infection with the Aichi strain (P = 0.0512) (Figures 13 
1A and 1B). Given that the inhibitory effect of diltiazem was the most pronounced and was 14 
similar to that of the intracellular Ca2+ chelator BAPTA-AM, which was previously shown to 15 
be an effective inhibitor of IAV infection (Fujioka et al., 2013), we chose this reagent for 16 
subsequent experiments. Next, to further evaluate the effect of CCBs on IAV infection in 17 
other mammalian cells than MDCK cells, we utilized immunofluorescence-based infection 18 
assay. This assay visualizes single-round replication at a single cell level (Figure S1C), and 19 
the percentage of NP-positive cells is correlated with the titer of infected viruses (Figure 20 
S1D), thereby expanding cell strains that can be analyzed. With this assay, we noticed that 21 
diltiazem also inhibited infection of PR8 in A549, MDCK, 293T, and Cos-1 cells (Figures 22 
1C and S1E) without remarkable cytotoxicity (Figure S1F). We next examined the effect of 23 
diltiazem on IAV-induced Ca2+ oscillations with the use of the Förster resonance energy 24 
transfer (FRET)-based Ca2+ sensor Yellow Cameleon (YC3.60) (Nagai et al., 2004) and found 25 
that it inhibited PR8- or Aichi-induced Ca2+ oscillations in both Cos-1 and A549 cells 26 
(Figures 1D, 1E, S1G, and S1H; Supplementary Movies 1, 2). Moreover, diltiazem also 27 
inhibited virus internalization (Figures 1F and 1G). Together, these results indicated that 28 
VDCCs contribute to IAV entry and subsequent infection. 29 
Knockdown of Cav1.2 Inhibits IAV-Induced Ca2+ Oscillations, IAV Internalization, and 30 
IAV Infection 31 
Among VDCC family members (L-, P/Q-, N-, R- and T-type channels), L-type VDCCs are 32 
expressed ubiquitously, including respiratory epithelia (Brennan et al., 2013), whereas non–L-33 
 5 
type channels show neuron- or sinus node-restricted expression patterns (Catterall, 2011; 1 
Catterall et al., 2005). In addition, among L-type channels, whereas Cav1.2 expression has 2 
been detected in a range of tissues, Cav1.1, Cav1.3 and Cav1.4 are expressed predominantly in 3 
skeletal muscle, neuroendocrine tissues and the retina, respectively (Catterall et al., 2005). 4 
The copy number of Cav1.2 mRNA was markedly higher than that of Cav1.1, Cav1.3 or 5 
Cav1.4 mRNAs in the human cell lines examined in the present study (Figure S2A). 6 
Knockdown of Cav1.2 (by up to ~60% as revealed by immunoblot analysis) (Figure S2B) in 7 
A549 cells by transfection with small interfering RNAs (siRNAs) inhibited PR8-induced Ca2+ 8 
oscillations, virus entry, and virus infection (Figures 2A–C). In addition, Cav1.2 knockdown 9 
inhibited PR8-induced Ca2+ oscillations as well as PR8 infection in 293T cells (Figures S2C 10 
and D). Furthermore, progeny virus production in Cav1.2-knockdown 293T cells was found to 11 
be inhibited, as evaluated by an MDCK plaque assay (Figure S2E). These results together 12 
indicated that the observed inhibitory effects of CCBs were not due to off-target actions and 13 
that Cav1.2 contributes to IAV infection in multiple cell contexts. 14 
HA Binds to Cav1.2 15 
To explore the molecular mechanism by which IAV activates Cav1.2, we exposed cells 16 
expressing YC3.60 to PR8 labeled with the lipophilic tracer DiD and then imaged them by 17 
time-lapse microscopy every 2 s. This approach allowed the monitoring of Ca2+ dynamics at 18 
virus attachment sites with high temporal resolution. Transient small increases in [Ca2+]i 19 
around some of the regions at which virus particles had adsorbed were detected before the 20 
robust increase in [Ca2+]i apparent throughout the entire cell (Figures S3A–C), suggesting 21 
that IAV might directly bind to and activate Cav1.2. To test this possibility, we performed a 22 
membrane binding assay (Côté et al., 2011) with a membrane fraction prepared from cells 23 
expressing either full-length Cav1.2 or fragments thereof (Figures 3A and 3B). We found that 24 
PR8 bound to full-length (FL) Cav1.2 (Figure 3C) and that this binding was partially 25 
inhibited by treatment with sialidase but not by the Ca2+ chelator EGTA (Figure 3C). These 26 
results indicated that sialylation of Cav1.2 is required for IAV binding, whereas Ca2+ is 27 
dispensable. Analysis of membrane fractions of cells expressing truncation mutants of Cav1.2 28 
revealed that IAV preferentially bound to fragment containing segment IV of Cav1.2 (Figure 29 
3D). It was recently reported that there are two potential sialylated asparagine residues 30 
(N1436 and N1487) in segment IV (Lazniewska and Weiss, 2017) (Figure 3B), suggesting 31 
that the HA glycoprotein might be responsible for binding of IAV to this fragment. To test 32 
this notion more directly, we performed a co-immunoprecipitation assay for HA and Cav1.2. 33 
 6 
HA is retained at the plasma membrane or virus surface through the transmembrane region at 1 
its COOH-terminus (Mair et al., 2014), and trimer formation by HA determines the rate of its 2 
transport for secretion (Ceriotti and Colman, 1990). We therefore constructed an expression 3 
vector for a form of HA in which the transmembrane region is replaced with a six-histidine 4 
(6×His) tag and a foldon domain, a natural trimerization domain from T4 bacteriophage 5 
fibritin (Meier et al., 2004) (Figure S3D). The modified HA protein (HA-His) would be 6 
expected to be secreted from cells as a trimer and to contact the cell surface region of Cav1.2. 7 
As expected, HA-His was detected in immunoprecipitates of full-length (FL) Cav1.2 or of 8 
fragment III-IV, but not in those of fragment I-II (Figures 3E and 3F). Given that the 9 
membrane-localized fraction of truncation mutants was comparable to that of full-length 10 
Cav1.2 (Figure S3E), the difference in precipitation might be accounted for by the difference 11 
in binding affinity to HA, but not by their localization. The binding of HA to fragment III-IV 12 
was partially inhibited by treatment with sialidase, suggesting that HA indeed binds to 13 
segment IV (or III) of Cav1.2 through sialylated residues (Figure S3F). 14 
HA Bindings to Cav1.2 through Glycosylated Asparagine Residues is Crucial for 15 
Calcium Oscillation and Virus Infection 16 
To examine further whether sialylation of Cav1.2 is required for the HA-Cav1.2 interaction, 17 
we constructed Cav1.2 mutants in which one or both of the potential sialylated asparagine 18 
residues in domain IV was replaced with glutamine (N1436Q, N1487Q and N1436Q + 19 
N1487Q). Expression of the wild-type form of fragment III-IV of Cav1.2 in 293T cells gave 20 
rise to two distinct bands, only the faster migrating of which was detected in cells expressing 21 
the mutants (Figure S4A). This result suggested that the slower migrating band (indicated by 22 
arrowhead) represented a form of the fragment that was glycosylated at N1436, N1487, or 23 
both residues. Indeed, the upper band of the wild-type fragment was no longer evident after 24 
treatment with peptide:N-glycosidase F (PNGase F), which inhibits IAV infection (Chu and 25 
Whittaker, 2004), whereas such treatment had no effect on the electrophoretic mobility of the 26 
mutants (Figure S4B). The binding of HA to the Cav1.2 mutants was attenuated compared 27 
with that apparent with the wild-type fragment (Figure 4A). The extent of this attenuation 28 
was similar to that induced by sialidase treatment (Figures 3C and S3F), suggesting that 29 
sialic acid-dependent binding of Cav1.2 to HA might be dictated by these asparagine residues. 30 
To provide more evidence for this notion, we performed rescue experiments, in which 31 
wild-type Cav1.2 or its glycosylation-deficient N1436Q + N1487Q mutant was introduced 32 
into A549 cells that had been depleted of endogenous Cav1.2 by transfection with an siRNA 33 
 7 
(siCav1.2#13) targeted to the 3' untranslated region of Cav1.2 mRNA. Whereas wild-type 1 
Cav1.2 restored single-round infection with IAV in the Cav1.2 knockdown cells, the mutant 2 
failed to do so (Figure 4B). Moreover, wild-type Cav1.2, but not the mutant protein, restored 3 
PR8-induced Ca2+ oscillations in the knockdown cells (Figure S4C). Given that the 4 
glycosylation deficient mutant could be localized at the plasma membrane to a similar extent 5 
as the wild-type form (Figure S4D), it was indicated that glycosylation at N1436 or N1487 6 
(or both residues) of Cav1.2 and the binding of these residues to HA are critical for Ca2+-7 
regulated virus infection. 8 
The CCB Diltiazem Inhibits IAV Infection In Vivo and Ex Vivo. 9 
To demonstrate the significance of VDCCs and its inhibition in IAV infection in vivo, we first 10 
confirmed that VDCC proteins were indeed expressed in viral target cells in the murine 11 
respiratory tissues by immunohistochemistry. Epithelia in the nasal cavity, trachea, and 12 
bronchioles, as well as alveolar macrophages were positive for the viral antigen NP protein 13 
(Figures 5A–D). In these cells, Cav proteins were shown to be expressed despite the 14 
difference in their abundance (Figures 5A–D), suggesting that Cav proteins are present in 15 
viral target cells in respiratory tissues and might be involved in IAV infection. 16 
 Under this condition, we examined the effect of the CCB diltiazem on IAV infection 17 
in vivo. Given that oral or intraperitoneal administration of diltiazem does not result in 18 
delivery of the drug to respiratory tissues (Sun et al., 2009), we administered PR8 (50 PFU) to 19 
anesthetized mice intranasally, treated the animals with diltiazem intranasally beginning 20 
either before or after virus exposure and examined the effect of the drug on viral replication in 21 
the nasal cavity (Figure 6A). Prophylactic administration of diltiazem resulted in a significant 22 
and dose-dependent reduction in the viral amount of nasal lavage fluid (Figures 6B and 23 
S5A); although this effect was less pronounced than that of the anti-influenza drug 24 
oseltamivir, the difference in the observed maximal effects of the two drugs was not 25 
significant. Diltiazem also inhibited virus replication when the treatment was initiated 1 day 26 
after exposure to PR8 (Figure 6C), with this effect being similar to that of oseltamivir. To 27 
further demonstrate the effectiveness of CCB to protect against lethal infection, mice were 28 
challenged with a higher dose of PR8 (104 PFU) and monitored for survival and body weight 29 
changes (Figures 6D and 6E). Diltiazem administration significantly prolonged survival and 30 
allowed the recovery of the survivors. Taken together, the CCB was thus effective as both a 31 
prophylactic and therapeutic agent to a wide range of doses of infection. 32 
 8 
 We also evaluated the effect of diltiazem on IAV infection to human respiratory 1 
epithelial cells. To this aim, the human bronchial epithelial cell line BEAS-2B was recruited. 2 
BEAS-2B cells were known to form spheroid (mimics of alveoli) and epithelial monolayer 3 
(mimics of bronchial epithelium) when cultured “on” and “in” Matrigel (Shen et al., 2015). 4 
After formation of either spheroid (Figure S5B) or monolayer (Figure S5C), the cells were 5 
then pre-treated with diltiazem and exposed to PR8. In both structures, IAV NP-positive cells 6 
were dramatically decreased by the treatment, affirming that the CCB was also effective 7 
human respiratory epithelial cells.  8 
 9 
DISCUSSION 1 
In this study, we have shown that Cav1.2 bound to IAV HA and functional analysis also 2 
revealed that Cav1.2 and its binding to HA through sialic acid were involved in IAV infection 3 
and IAV-induced Ca2+ oscillation. These observations together demonstrated Cav1.2 as one of 4 
the key cell surface molecules for IAVs to hijack host cell machinery for their efficient 5 
incorporation into cells and subsequent infection. Given that the sequence of sialic acid 6 
binding site of HA is highly conserved across the serotypes, whereas antigen drift is 7 
frequently observed in other parts, the findings presented here are expected to lead to the 8 
development of a novel approach to inhibit IAV infection by targeting the HA-calcium 9 
channel interaction. Such therapeutics appears to be effective to a range of serotypes and 10 
tolerant to drug resistant strains. 11 
 Extensive studies have been performed to identify sialylated cell surface proteins that 12 
mediate the virus-host cell interaction via binding to HA protein over the past years (Achdout 13 
et al., 2010; Arnon et al., 2004; Eierhoff et al., 2010; Ho et al., 2008; Mandelboim et al., 14 
2001). However, no protein has been identified as a key host cell receptor for IAV so far; that 15 
is, the viruses still infect cells even in the presence of inhibitors for respective molecules or in 16 
the absence of the target molecules through knockdown experiments (Eierhoff et al., 2010). 17 
Therefore, identification of a protein(s) that is critical for IAV adsorption to host cells and 18 
subsequent infection has yet to be eagerly anticipated. One of the reason why such a wide 19 
variety of proteins are identified as a binding partner for HA, but are not involved in IAV 20 
entry and infection, might be accounted partly for by the abundance of sialylated proteins on 21 
the cell surface; viz. when there is an abundant protein that is modified by α2,3-linked or 22 
α2,6-linked sialic acids at many sites and is irrelevant to IAV infection, the sensitivity to 23 
detect the real targets can be decreased markedly. Another possible reason that makes 24 
molecular identification difficult might be accounted for by non-specific or sialic acid-25 
independent binding to HA. In this study, binding of glycosylation-deficient mutants of 26 
Cav1.2 was significantly reduced (by ~40%) than that of wild type, but not abolished 27 
completely (Figure 4A), suggesting that Cav1.2 may also bind to HA at multiple extracellular 28 
regions in a manner independent of sialic acid. Accordingly, sialidase treatment also 29 
displayed partial inhibitory effect on the binding (Figures 3C and S3F). 30 
 Although we here show that IAV bound to N1436 and N1487 residues in segment IV 31 
of Cav1.2 to evoke host cell Ca2+ signaling and facilitate infection (Figures 4B and S4C), the 32 
molecular mechanism through which the binding induces Ca2+ influx has not been clarified. 33 
 10 
The possible mechanisms include: 1) an increase in channel conductance, 2) an increase in 1 
opening probability of the channel, and 3) decreased interaction of α1 and other subunits. 2 
Several reports implicate glycosylation of calcium channels in their function. For example, 3 
Cav1.2, is glycosylated at two asparagine residues in domain I in addition to N1436 and 4 
N1487 in domain IV (Lazniewska and Weiss, 2017), and mutation in the asparagine residues 5 
in domain I caused a depolarizing shift in voltage-dependent gating of rabbit Cav1.2 (Park et 6 
al., 2015). Furthermore, glycosylation at asparagine N192 and N1466 in segments I and III of 7 
the human low-voltage-gated T-type calcium Cav3.2 plays an essential role in the conducting 8 
function by enhancing the permeability and/or the pore opening of the channel (Ondacova et 9 
al., 2016). Therefore, it is possible that binding of HA to asparagine residues through sugar 10 
chains modulates channel functions, although glycosylation in segment IV per se does not 11 
affect voltage-dependent gating (Park et al., 2015). 12 
VDCC is a multimeric complex that consists of α1, α2, β, δ, and γ (Catterall, 2011; 13 
Catterall et al., 2005). In particular, interaction of α1 subunit to β subunit through highly 14 
conserved α-interaction domain within the cytoplasmic loop between the domains I and II of 15 
α1 subunit is critical in determining VDCCs properties, including channel gating (Budde et al., 16 
2002; Buraei and Yang, 2013). Given that the interaction with β subunits often suppresses 17 
channel activity through shift of the voltage dependence to more hyperpolarized voltages and 18 
promotion of voltage-dependent inactivation (Dolphin, 2012; Meir et al., 2000), it is therefore 19 
possible that binding of HA to Cav1.2 interferes the interaction and activates VDCCs through 20 
derepression. 21 
 Cav1.2 contains consensus sequences for glycosylation with N-linked glycan (N-X-T) 22 
at 1436 and 1487 in the domain IV (Lazniewska and Weiss, 2017), and glycosylation at these 23 
asparagine residues were demonstrated to be important for IAV-induced [Ca2+]i increase 24 
(Figure S4C). Such N-glycosylation sites are not conserved in other VDCC isoforms except 25 
for Cav2.2, which possesses a potentially sialylated asparagine residue (N1675) in the 26 
segment IV (Lazniewska and Weiss, 2017). Regarding other type of channels, there exist a 27 
large number of possible glycosylated asparagine residues (Lazniewska and Weiss, 2017). 28 
Although significance of glycosylation at these sites is unclear, it is therefore possible that the 29 
sialylated channels other than Cav1.2 also bind to HA and play a role in influenza virus 30 
infection. Nevertheless, given the tissue or cell-type restricted expression pattern of other 31 
types of channels than Cav1.2, global significance of the contribution of such channels should 32 
be further demonstrated in the future. 33 
 11 
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FIGURE LEGENDS 
Figure 1. Pharmacological Inhibition of VDCCs Suppresses IAV Replication, IAV 
Internalization, and IAV-Induced Ca2+ Oscillations. 
(A, B) Replication of PR8 (A) or Aichi (B) in the absence (–) or presence of the indicated 
agents was determined with an MDCK cell plaque assay. Data are means ± s.e.m. (n = 3). *P 
< 0.01, **P < 0.001 versus nontreated cells, as calculated by one-way ANOVA with 
Dunnett’s post-test. PFU, plaque-forming units. 
(C) Effect of diltiazem on PR8 infection in the indicated cell lines as evaluated with an 
immunofluorescence-based assay. Data are means ± s.e.m. (n = 3). *P < 0.05, **P < 0.001 
versus nontreated cells, as calculated by Student’s t test. NP, nucleoprotein. 
(D, E) Effect of diltiazem on PR8-induced Ca2+ oscillations in Cos-1 cells monitored with the 
FRET-based Ca2+ sensor YC3.60. FRET/CFP (cyan fluorescent protein) ratio images are 
shown in intensity-modified display (IMD) mode, and the upper and lower limits of the ratio 
range are indicated. Bar, 10 μm (D). Representative traces for the normalized FRET/CFP 
emission ratio are shown in E. 
(F, G) Effect of diltiazem on PR8 internalization in Cos-1 cells as evaluated with an 
immunofluorescence-based assay. Representative images are shown. Boxed regions on the 
left are shown at higher magnification on the right. Bar, 10 µm (F). Rab7- and NP-positive 
regions were extracted and their co-localization was determined (G). Data are means ± s.e.m. 
(n > 28). *P = 0.013 versus nontreated cells, as calculated by Student’s t test. See also Figure 
S1 and Supplementary Movies 1, 2. 
 
Figure 2. Knockdown of Cav1.2 Inhibits IAV-Induced Ca2+ Oscillations, IAV 
Internalization, and IAV Infection. 
(A) A549 cells were transfected first with an siRNA specific for Cav1.2 mRNA (siCav1.2#2 
or -#13) or with a scrambled siRNA (siControl) for 48 h and then with an expression vector 
encoding YC3.60 for 24 h. The cells were then monitored by dual-emission microscopy with 
exposure to PR8 at time 0. Representative traces for the normalized emission ratio are shown. 
(B, C) A549 cells transfected with siRNAs as in A were examined for PR8 internalization (n 
> 40) (B) and infection (n > 5) (C) with immunofluorescence-based assays. Data are means ± 
s.e.m.  *P < 1 × 10–6 (B) or *P < 0.002 (C) versus control cells, as calculated by one-way 
ANOVA with Dunnett’s post-test. See also Figure S2. 
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Figure 3. HA of IAV Binds to Cav1.2. 
(A) Schematic representation of the membrane binding assay. IB, immunoblot analysis. 
(B) Structure of Cav1.2 and sialylated asparagine residues in segment IV. 
(C, D) Binding of PR8 to CFP-tagged full-length (FL) Cav1.2 in the absence or presence of 
sialidase (S) or EGTA (E) (c) or to the indicated FLAG epitope-tagged fragments of Cav1.2 
(D) was examined with the membrane binding assay. Representative immunoblot analysis 
with antibodies to the M1 protein of IAV and to Cav1.2 (left) as well as quantitative data 
(means ± s.e.m., right) are shown. *P = 0.016 versus nontreated cells (n = 4), as calculated by 
one-way ANOVA with Dunnett’s post-test (C); *P < 0.03 versus full-length Cav1.2 (n = 3), 
as calculated by one-way ANOVA with Dunnett’s post-test (D). Arrowheads indicate bands 
corresponding to the expected sizes of the Cav1.2 fragments. 
(E–F) Co-immunoprecipitation analysis of the binding of a 6×His-tagged form of HA (HA-
His) to full-length (E) or fragments of (F) of Cav1.2 in 293T cells. CFP- or FLAG-tagged 
forms of Cav1.2 were immunoprecipitated (IP) with antibodies to green fluorescent protein 
(GFP) or to FLAG, respectively. Representative immunoblot analysis and quantitative data 
for co-immunoprecipitated HA-His (means ± s.e.m., n = 3) are shown. *P < 0.04 versus wild-
type Cav1.2, as calculated by one-way ANOVA with Dunnett’s post-test. Arrowheads 
indicate bands corresponding to the expected sizes of the Cav1.2 fragments. See also Figure 
S3. 
 
Figure 4. Glycosylation of Cav1.2 at Asn1436 or Asn1487 is Critical for IAV Infection. 
(A) Co-immunoprecipitation analysis of the binding of a 6×His-tagged form of HA (HA-His) 
to glycosylation-deficient mutants of Cav1.2 in 293T cells. CFP- or FLAG-tagged forms of 
Cav1.2 were immunoprecipitated (IP) with antibodies to GFP or to FLAG, respectively. 
Representative immunoblot analysis and quantitative data for co-immunoprecipitated HA-His 
(means ± s.e.m., n = 3) are shown. *P < 0.04 versus wild-type Cav1.2, as calculated by one-
way ANOVA with Dunnett’s post-test. Arrowheads indicate bands corresponding to the 
expected sizes of the Cav1.2 fragments. 
(B) A549 cells transfected with Cav1.2 or control siRNAs were further transfected with 
expression vectors for wild-type or a glycosylation-deficient mutant of Cav1.2 and were then 
subjected to an immunofluorescence-based assay of PR8 infection. Data are means ± s.e.m. (n 
= 3). *P < 0.05 versus control cells as calculated by one-way ANOVA with Dunnett’s post-
test. See also Figure S4. 
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Figure 5. Immunohistochemical Examination of IAV-Infected Mice 
Representative pathological images of the nasal cavity (A), tracheae (B), and lungs 
(bronchiole (C) and alveoli (D)) of PR8 infected mice with hematoxylin and eosin staining (H 
& E; left panels), with immunohistochemistry for Cav (middle panels), and IAV NP (right 
panels). The lower panels in each subpanel were higher magnification images of the upper 
images. Bar, 50 μm. 
 
Figure 6. The CCB Diltiazem Inhibits IAV Replication In Vivo. 
(A) Protocol for in vivo experiments. 
(B, C) The effect of prophylactic (B) or therapeutic (C) administration of diltiazem on IAV 
replication was evaluated by measurement of infectious virus particles in nasal lavage fluid 
and was compared with that of oseltamivir. Data are means ± s.e.m. (n > 3). *P < 1 × 10–4 (B) 
or *P < 0.001 (C) versus nontreated animals, as calculated by one-way ANOVA with 
Dunnett’s post-test. A.U., arbitrary units. 
(D, E) The effect of diltiazem on survival and body weight of mice infected with IAV. Mice 
were prophylactically administrated as in (A) and then infected with a sublethal dose of PR8 
(104 PFU). Survival rate (D) and changes in body weight (E) were monitored for 14 days after 
infection. (n = 6). P values versus nontreated animals, as calculated by one-way ANOVA 
with log rank test (D) or Mauchly’s sphericity test (E), are indicated in the graphs. See also 
Figure S5. 
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STAR METHODS 1 
CONTACT FOR REAGENT AND RESOURCE SHARING 2 
Further information and requests for resources and reagents should be directed to and will be 3 
fulfilled by the Lead Contact, Yusuke Ohba (yohba@med.hokudai.ac.jp). 4 
 5 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 6 
Mice 7 
Mouse experiments were approved and conducted in accordance with the guidelines 8 
established by the Hokkaido University Committee and National Institute of Infectious 9 
Diseases on Animal Care and Use. Male C57BL/6J or female BALB/c mice were housed 10 
under specific pathogen–free conditions at 21°C and 31% humidity. At least four mice for 11 
each group at 6–8 weeks of age were subjected to experiments. 12 
Cell lines 13 
Cos-1 (JCRB9082), HEK293T (ATCC CRL-11268), HeLa (CCL-2), A431 (CRL-1555), 14 
A549 (CCL-185), and BEAS-2B (ATCC CRL-9609) cells were maintained under a 15 
humidified atmosphere of 5% CO2 at 37°C in Dulbecco’s modified Eagle’s medium (DMEM) 16 
supplemented with 10% fetal bovine serum (Thermo Fisher Scientific), whereas MDCK cells 17 
(CCL-34) were maintained in minimum essential medium (MEM) (Sigma-Aldrich) 18 
supplemented with 10% fetal bovine serum. Expression vectors were introduced into cells by 19 
transfection with the use of Polyethylenimine “Max” (Polysciences). 20 
Purification of viruses 21 
IAV strains A/Puerto Rico/8/34 (H1N1; PR8) and A/Aichi/2/68 (H3N2; Aichi) were 22 
propagated for 48 h at 37°C in the chorioallantoic cavity of 10-day-old embryonated chicken 23 
eggs. Alternatively, MDCK cells were infected with viruses at a multiplicity of infection 24 
(MOI) of 0.0001 plaque-forming unit (PFU) per cell for 48 h at 37°C. Viruses isolated by 25 
high-speed centrifugation were resuspended in phosphate-buffered saline and stored at –80°C 26 
until use. The amount of infectious virus in culture supernatants was determined with a plaque 27 
assay. 28 
 20 
METHOD DETAILS 1 
Plasmids. 2 
Expression vectors for the FRET-based biosensor YC3.60 (Nagai et al., 2004) were kindly 3 
provided by A. Miyawaki (RIKEN). Human Cav1.2 cDNA was prepared from total RNA of 4 
293T cells by reverse transcription (RT) and the polymerase chain reaction (PCR) with the 5 
primers CAV12_F and CAV12_R. The coding sequences for fragments I-II, I-III, I-IV and 6 
III-IV of Cav1.2 were amplified by PCR with the primers CAV12_F and II_R; CAV12_F and 7 
III_R; CAV12_F and IV_R; and III_F and IV_R, respectively. All PCR products were 8 
subcloned into the XhoI and NotI sites of the pCAGGS-Flag-IRES-ExRed or pFX-SECFP 9 
vectors (Fujioka et al., 2013; Horiguchi et al., 2017). The cDNAs encoding the N1436Q or 10 
N1487Q mutants of Cav1.2 were obtained by PCR-based mutagenesis with the use of a 11 
QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) and with the primer pairs 12 
N1436Q_F and N1436Q_R or N1487Q_F and N1487Q_R. 13 
 To generate plasmids encoding the target sequences of Cav1.1–Cav1.4 for quantitative 14 
PCR (qPCR), the cDNA of 293T cells were amplified with primers Cav1.1-F and Cav1.1-R, 15 
Cav1.2-F and Cav1.2-R, Cav1.3-F and Cav1.3-R, as well as Cav1.4-F and Cav1.4-R, and the 16 
resulting PCR products were subcloned into pCR-Blunt II-TOPO (Thermo Fisher Scientific). 17 
 cDNA for HA of PR8 was a kind gift from K. Kihatsu (Osaka University) and its 18 
coding sequence was amplified by PCR with the primers PR8HA_F and PR8HA_R and was 19 
subcloned into the EcoRI and XhoI sites of a modified pCA7 vector (Takeda et al., 2005). The 20 
encoded protein consists of HA1, the ectodomain of HA2, foldon (a natural trimerization 21 
domain of T4 bacteriophage fibritin) (Meier et al., 2004), and a 6×His tag (Figure S3D). 22 
 cDNA for Sirius was kindly provided by T. Nagai (Osaka University; (Tomosugi et al., 23 
2009) and its coding sequence was amplified by PCR with the primers Sirius_F and Sirius_R 24 
and was subcloned into the XhoI and NotI sites of pFX-CAAX (Fujioka et al., 2013; 25 
Horiguchi et al., 2017). 26 
Cytotoxicity assay 27 
Cells were cultured in 96 well plates in the absence or presence of CCBs or BAPTA-AM for 28 
48 h (Figure S1B) or for 6 h (Figure S1F), fixed with 3% paraformaldehyde, and then 29 
stained with Gram’s crystal violet solution (Merck). The cells were washed with distilled 30 
water and air-dried. The absorbance at 590 nm was measured by the SpectraMax i3x Multi-31 
Mode microplate reader (Molecular Devices), based on which cell viability (or cytotoxicity of 32 
drugs) was determined. 33 
 21 
Fluorescent labeling of viruses 1 
For preparation of fluorescently labeled PR8, 1 ml of purified virus suspension (0.4 mg/ml) 2 
was incubated with 100 μM DiD stock solution in the dark for 1 h at room temperature 3 
(Nanbo et al., 2010). 4 
Plaque assay 5 
A plaque assay was performed as described previously (Pleschka et al., 2001; Yoshida et al., 6 
2009). In brief, confluent monolayers of MDCK cells in 12-well plates were inoculated with 7 
the conditioned medium of virus-infected cells or directly with virus suspension. After culture 8 
for 1 h, the culture supernatants were removed and the cells were overlaid with MEM 9 
containing 1% Bacto-agar and trypsin (5 μg/ml). Plaques were counted after incubation of the 10 
cells at 35°C under 5% CO2 for 2 days. 11 
Immunofluorescence-based virus internalization and infection assays 12 
Immunofluorescence-based virus internalization and infection assays were performed as 13 
described previously (Fujioka et al., 2013). In brief, serum-deprived cells were either treated 14 
with inhibitors for 30 min or left untreated and then incubated with IAV at an MOI of 10 PFU 15 
per cell for 1 h (internalization assay) or at an MOI of 1 PFU per cell for 4 h (infection assay). 16 
Cells were then fixed with 3% paraformaldehyde for 15 min at room temperature, 17 
permeabilized with 0.1% Triton X-100 in phosphate-buffered saline for 4 min at room 18 
temperature and then incubated with 1% bovine serum albumin to block nonspecific binding 19 
of antibodies. The cells were further incubated with primary antibodies (NP, 1:1,000 dilution; 20 
Rab7, 1:250 dilution) overnight at 4°C, after which immune complexes were detected by 21 
incubation for 1 h at room temperature in the dark with AlexaFluor488-, AlexaFluor594- or 22 
AlexaFluor647-conjugated secondary antibodies (1:250 dilution). Nuclei were visualized by 23 
staining with Hoechst 33342. Images were acquired with an FV-10i confocal microscope 24 
(Olympus) for the internalization assay or with a wide-field fluorescence microscope (IX-81, 25 
Olympus) for the infection assay. 26 
 For analysis of virus internalization, confocal sections (with a z step of 0.2 μm) were 27 
acquired from the bottom to the top of cells and subjected to background subtraction. Vesicles 28 
positive for NP or Rab7 were extracted with the use of the ‘granularity’ module of 29 
MetaMorph software (SCR_002368, Universal Imaging), and the co-localization of NP with 30 
Rab7 was quantified with the ‘measure co-localization’ function. For analysis of virus 31 
infection, the fluorescence intensity of NP in the nucleus was measured and the percentage of 32 
NP-positive cells was determined. 33 
 22 
Fluorescence microscopy and FRET analysis 1 
FRET imaging and data analysis were performed essentially as described previously (Fujioka 2 
et al., 2013; Ohba et al., 2003). In brief, cells were transfected with a vector for YC3.60 for 24 3 
h, deprived of serum for 4 h and placed in a stage-top incubation chamber (Live Cell 4 
Instrument) at 37°C on an Olympus IX-81 microscope equipped with a BioPoint MAC6000 5 
filter and shutter control unit (Ludl Electronic Products), an automated XY-stage (Chuo 6 
Precision Industrial) and a Cool SNAP MYO cooled charge-coupled device camera 7 
(Photometrics). Cells were illuminated with a SOLA Light Engine (Lumencor) through an 8 
FF02-438/24 excitation filter (Semrock), and cyan fluorescent protein (CFP) and FRET 9 
fluorescence images obtained through FF01-483/32 and FF01-542/27 emission filters 10 
(Semrock), respectively, were recorded every 30 s. After 10 to 15 min, the cells were infected 11 
with IAV at an MOI of 1 PFU per cell. In some experiments, cells were exposed to inhibitors 12 
for 30 min before infection. FRET efficiency (FRET/CFP emission ratio) was calculated as 13 
the quotient of background-subtracted FRET and CFP images and was presented in an 14 
intensity-modified display (IMD) mode with MetaMorph software. Eight colors from red to 15 
blue were used to represent the emission ratio, with the intensity of each color indicating the 16 
mean intensity of FRET and CFP as indicated. 17 
 To determine the cell surface expression levels of VDCCs, 293T cells were 18 
transfected with expression vectors for either wild-type form, truncation form, or 19 
glycosylation-deficient mutant form of FLAG-tagged Cav1.2, along with that for Sirius-20 
CAAX (marker for plasma membrane) for 24h. The cells were then subjected to 21 
immunofluorescence with the use of an anti-FLAG antibody. Mask images for plasma 22 
membrane were generated by binary images of Sirius-CAAX, whereas those for entire cell 23 
area were generated by filling the inside of CAAX-positive region. Fluorescence intensities in 24 
the plasma membrane region and entire cell region were thereby quantified, assumed as the 25 
expression level of Cav1.2 in each region, and plotted. 26 
Immunoblot analysis 27 
Unless otherwise specified, cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.4), 150 28 
mM NaCl, 0.25% Fos-choline, 1 mM CaCl2, 1 mM MgCl2, 1 mM phenylmethylsulphonyl 29 
fluoride, 1 mM Na3VO4, cOmplete Protease Inhibitor Cocktail (Sigma-Aldrich)) for 30 min 30 
on ice. The lysates were centrifuged at 20,000 × g for 10 min at 4°C, and the resulting 31 
supernatants were subjected to SDS-polyacrylamide gel electrophoresis. The separated 32 
proteins were transferred to a polyvinylidene difluoride membrane (Bio-Rad) and subjected to 33 
 23 
immunoblot analysis. Immune complexes were detected with the use of ECL Western 1 
Blotting Detection Reagent (GE Healthcare) and an LAS-1000UVmini image analyzer 2 
(Fujifilm). 3 
Immunoprecipitation 4 
Cells were lysed and the lysates centrifuged as described for immunoblot analysis, and the 5 
resulting supernatants were incubated with primary antibodies for 1 h at 4°C with gentle 6 
rotation before the addition of protein G– or protein A–Sepharose beads (GE Healthcare) and 7 
further incubation for 1 h. The bead-bound immune complexes were isolated by 8 
centrifugation, washed twice with lysis buffer, eluted in SDS sample buffer and subjected to 9 
immunoblot analysis. 10 
Membrane binding assay 11 
293T cells were transfected for 24 h with expression vectors for full-length or fragments of 12 
Cav1.2 and then resuspended in Tris-buffered saline containing 1 mM Na3VO4. A membrane 13 
fraction of the cells was prepared by freeze-thawing and subsequent centrifugation at 20,400 14 
× g for 10 min at 4°C and was incubated for 12 h at 4°C in a 96-well plate coated with 15 
antibodies to Cav1.2 (AB_2039771, Alomone Labs). After washing with Tris-buffered saline 16 
containing 1 mM Na3VO4, the wells of the plate were further incubated with PR8 for 1 h at 17 
4°C. After extensive washing, the material adsorbed to each well was eluted in SDS sample 18 
buffer and subjected to immunoblot analysis. 19 
RNA interference 20 
The siRNAs targeting human Cav1.2 mRNA (siCav1.2#2, Hs_Cav1.2_2; siCav1.2#13, 21 
Hs_Cav1.2_13) were obtained from Qiagen and were introduced into cells by transient 22 
transfection with the use of the Lipofectamine RNAiMax reagent (Thermo Fisher Scientific). 23 
AllStars Negative Control siRNA (Qiagen) was used as a control. 24 
RNA isolation, RT and quantitative PCR analysis 25 
Total RNA was isolated from cells with the use of an RNeasy Mini Kit (Qiagen), and portions 26 
of the RNA (2.0 μg) were subjected to RT with SuperScript VILO reverse transcriptase 27 
(Thermo Fisher Scientific). Quantitative PCR analysis was performed with the use of a 28 
StepOne real-time PCR system (Thermo Fisher Scientific) and the following primers: Cav1.1-29 
F and Cav1.1-R, Cav1.2-F and Cav1.2-R, Cav1.3-F and Cav1.3-R, Cav1.4-F and Cav1.4-R. 30 
The copy number of each Ca2+ channel was then determined by extrapolation from a 31 
calibration curve that was obtained by qPCR with calibrator plasmids as a template. 32 
 24 
3D culture 1 
BEAS-2B cells (3 × 104) were cultured on or in Matrigel (BD-Discovery Labware) in a 35 2 
mm glass-based dish for 5 days. After confirming monolayer or spheroid formation, the cells 3 
were further cultured in the presence of absence of diltiazem for 2 h, exposed to PR8 at an 4 
MOI of 1 PFU/cell, and subjected to immunofluorescence with the use of antibodies to IAV 5 
NP and Cav1.2. Nuclei were counterstained with Hoechst33342. The samples were observed 6 
under confocal microscopy. 7 
Animal experiments 8 
Six-week-old male C57BL/6J mice and eight-week-old female BALB/c mice were infected 9 
by direct delivery of PR8 (50–3 × 104 PFU) to the nares with a micropipette under isoflurane 10 
anesthesia, as described previously (Edenborough et al., 2012; Ng et al., 2010). The mice 11 
were housed separately for 3 days after virus exposure. Diltiazem (10 or 20 mg/kg/day) or 12 
oseltamivir (40 mg/kg/day) was administered intranasally or intraperitoneally beginning 13 
either 1 day before or 1 day after virus exposure. Nasal lavage fluid was collected 3 days after 14 
virus exposure and was assayed for the amount of infectious virus with the 15 
immunofluorescence-based infection assay. To monitor survival and body weight changes at 16 
lethal dose of IAV infection, at least six mice were infected with PR8 (104 PFU) as described 17 
above. The mice were housed and monitored separately for 14 days after virus exposure. 18 
Diltiazem (20 mg/kg/day) or oseltamivir (40 mg/kg/day) was administered intranasally or 19 
intraperitoneally, respectively, beginning 1 day before virus exposure. 20 
 To perform immunohistochemical experiments, mice were euthanized at 2 days post-21 
infection. Excised tissues preserved in 4% paraformaldehyde for 12 h were subsequently 22 
processed for paraffin embedding and cut into 3-μm-thick sections. One section from each 23 
tissue sample was stained using a standard hematoxylin and eosin procedure, and the others 24 
were subjected to immunohistochemistry. For visualization of replicated influenza viruses, a 25 
rabbit polyclonal NP antibody (Iwasaki et al., 1999) was used as a primary antibody after 26 
heat-mediated antigen retrieval in citrate buffer at 121ºC for 10 min. Immunohistochemistry 27 
for Cav proteins was performed with a rabbit polyclonal anti-panCav α antibody 28 
(AB_2039762, Alomone Labs) as a primary antibody after antigen retrieval in 0.025% trypsin 29 
solution at 37ºC for 30 min. A peroxidase-labeled polymer-conjugated anti-rabbit 30 
immunoglobulin (Dako) was used as a secondary antibody. Immune complexes were 31 
visualized by means of 3,3’-diaminobenzidine tetrahydrochloride staining. Hematoxylin 32 
(Modified Mayer’s) was used as a nuclear counterstain. 33 
 25 
QUANTIFICATION AND STATISTICAL ANALYSIS 1 
Quantitative data are presented as means ± s.e.m. from at least three independent experiments 2 
(unless indicated otherwise) and were compared by Student’s t test (between two conditions) 3 
or by one-way analysis of variance (ANOVA) followed by Dunnett’s post-hoc analysis 4 
(among multiple conditions), log rank test (Figure 6D) or Mauchly’s sphericity test (Figure 5 
6E). 6 
 7 
 8 
SUPPLEMENTARY INFORMATION 9 
Supplemental Movie 1. Representative Video Images of IAV-Induced Ca2+ Oscillations 10 
(Related to Figures 1D and E). 11 
Cos-1 cells expressing YC3.60 were monitored by dual-emission, time-lapse microscopy with 12 
exposure to PR8. The upper and lower limits of the emission ratio in IMD mode were set to 13 
4.0 and 2.8, respectively. 14 
 15 
Supplemental Movie 2. Representative Video Images of IAV-Induced Ca2+ Oscillations 16 
in The Presence of Diltiazem (Related to Figures 1D and E). 17 
Cos-1 cells expressing YC3.60 were treated with diltiazem and then monitored by dual-18 
emission, time-lapse microscopy with exposure to PR8. The upper and lower limits of the 19 
emission ratio in IMD mode were set to 4.0 and 2.8, respectively. 20 
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